VEGFA and neoplasm: Tumor-derived EVs can transport proangiogenic molecules into endothelial cells, promoting their angiogenic activity through the VEGF/VEGF to receptor, Notch, Wingless-type (WNT), and Hypoxia-inducible factor (HIF) signaling pathways [29,30].